Moderna Inc (NASDAQ:MRNA) is trading higher Wednesday after the company filed for authorization of its COVID-19 vaccine, a 50 microgram two-dose series of SPIKEVAX, with Health Canada to include children ages six to 11.
Moderna納斯達克(Sequoia Capital)週三股價上漲，此前該公司向加拿大衞生部申請批准其新冠肺炎疫苗，這是一種50微克兩劑的SPIKEVAX疫苗，包括6至11歲的兒童。
Health Canada approved the New Drug Submission for SPIKEVAX for active immunization to prevent COVID-19 in individuals 12 years of age and older on Sept. 16.
加拿大衞生部於9月9日批准了SPIKEVAX的新藥提交，用於主動免疫，以預防12歲及以上的個人出現新冠肺炎。
Moderna recently shared new data from a study in children ages 6 years to 11 years. Vaccine efficacy of 100% using the Phase 3 COVE study primary case definition for COVID-19 was observed two weeks after the first dose of SPIKEVAX at the 50 microgram dose level.
莫德納最近分享了一項對6歲至11歲兒童進行的研究的新數據。按照第3期Cove研究新冠肺炎的主要病例定義，在首劑劑量為50微克的SPIKEVAX兩週後觀察到100%的疫苗效力。
Moderna said it plans to submit the data to other regulatory agencies around the world.
現代表示，它計劃將數據提交給世界各地的其他監管機構。
"We are encouraged that the Moderna COVID-19 vaccine at the 50 µg dose level helped prevent SARS-CoV-2 infection in children. We plan to submit these data to other regulatory agencies around the world to protect this important younger age population with our COVID-19 vaccine," said Stéphane Bancel, CEO of Moderna.
我們感到鼓舞的是，50微克劑量的現代新冠肺炎疫苗有助於預防兒童感染SARS-CoV-2。我們計劃將這些數據提交給世界各地的其他監管機構，以用我們的新冠肺炎疫苗保護這一重要的年輕人羣。斯特凡納銀行(Stéphane Bancel)，現代公司首席執行官。
See Also: Can Moderna Deliver A Highly Effective Flu Vaccine?
另見：莫迪納能提供高效流感疫苗嗎？
MRNA Price Action: Moderna has traded as high as $497.49 and as low as $88.61 over a 52-week period.
MRNA價格行為：在52周的時間裏，現代股票的交易價格最高為497.49美元，最低為88.61美元。
The stock was up 5.12% at $246.27 at time of publication.
截至發稿時，該股上漲5.12%，至246.27美元。
Photo: mufidpwt from Pixabay.
圖片來源：來自Pixabay的mufidpwt。
免責聲明：中文翻譯由騰訊翻譯君提供支持，富途對翻譯信息的準確性或可靠性所造成的任何損失不承擔任何責任。
風險提示：上文所示之作者或者嘉賓的觀點，都有其特定立場，投資決策需建立在獨立思考之上。富途將竭力但卻不能保證以上內容之準確和可靠，亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。
沒有留言:
張貼留言